期刊文献+

肿瘤血管抑制剂DX-1002结构的NMR确证

Structural identification of tumor angiogenesis inhibitor DX-1002 by NMR
下载PDF
导出
摘要 该文采用核磁共振的氢谱、碳谱和相关谱技术,同时结合质谱和红外光谱等技术,对DX-1002的化学结构进行解析。结果表明DX-1002的氢谱(1H-NMR)和碳谱(13C-NMR)各个化学位移值与DX-1002各个氢原子和碳原子的归属一致;结合同核化学位移相关谱(g COSY)、异核多量子关系谱(g HMQC)、核欧佛豪瑟效应频谱(NOESY)等综合分析,确定分子的空间结构;然后综合质谱和红外光谱确定DX-1002的化学结构为(E)-3-(3″-羟基-4″-甲氧苯基)-2-(3′,4′,5′-三甲氧基苯基)丙烯酸正丁铵盐。 The spectrums of1H-NMR and13C-NMR and others in combination with MS and IR were applied to analyze the chemical structure of tumor angiogenesis inhibitor DX-1002. Experimental results indicate that the chemical shifts of the1H-NMR and13C-NMR are consistent with the hydrogen atoms and carbon atoms of DX-1002. The spatial structure of molecules was determined on the basis of g COSY,g HMQC and NOESY. And then the chemical structure of DX-1002 was confirmed via mass spectrum and infrared spectrum to be(E)-3-(3″-hydroxy-4″-methoxyl phenyl)-2-(3′,4′,5′-triethoxyphenyl) N-butyl acrylate ammonium salt.
出处 《中国测试》 北大核心 2015年第11期55-58,共4页 China Measurement & Test
基金 东莞市引进创新创业领军人(201476815)
关键词 核磁共振 DX-1002 结构确证 肿瘤血管抑制剂 NMR DX-1002 structural identification tumor angiogenesis inhibitor
  • 相关文献

参考文献2

二级参考文献17

  • 1Pettit GR, Singh SB, Hamel E, et al. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatinA4 [ J ]. Experientia, 1989,45 : 205 - 211.
  • 2Pettit GR, Temple C, Narayanan VL, et al. Antineoplastic agents 322. synthesis of combretastatin A -4 prodrugs[J]. Anticancer Drug Des, 1995,10 : 299 - 309.
  • 3Brooks AC, Nash GE, Parkins CS, et al. Combretastatin A - 4- phosphate (CA -4 -P) induces neutrophil recruitment to cultured endothelial cells under flow[J]. J Vase Res, in Press, 2001.
  • 4Dark GD, Hill SA, Prise VE, et al. Combretastatin A - 4, an agent that displays potent and selective toxicity toward tumor vasculature[ J]. Cancer Res, 1997,57 : 1829 - 1834.
  • 5George RP, Monte RR. Antineoplastic agents 389. new syntheses of the combretastatin A -4 Prodrug [ J ]. Anti - Cancer Drug Design ,1998, 13:183 - 191.
  • 6Catharine M. L. West,Pat Price.Combretastatin A4 phosphate[J]. Anti-Cancer Drugs . 2004 (3)
  • 7Xiaojing Wang,Zhihang Chen,Jinjing Che,Qingfang Meng,Chengqi Shan,Yunan Hou,Xiaolei Liu,Yifeng Chai,Yuanguo Cheng.Development of a rapid and sensitive LC–MS/MS assay for the determination of combretastatin A4 phosphate, combretastatin A4 and combretastatin A4 glucuronide in beagle dog plasma and its application to a pharmacokinetic study[J]. Journal of Chromatography B . 2009 (30)
  • 8G. R. Pettit,S. B. Singh,E. Hamel,C. M. Lin,D. S. Alberts,D. Garcia-Kendal.Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4[J]. Experientia . 1989 (2)
  • 9Siemann Dietmar W,Chaplin David J,Walicke Patricia A.A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert opinion on investigational drugs . 2009
  • 10Tozer G M,Kanthou C,Baguley B C.Disrupting tumour blood vessels. Nature Reviews Cancer . 2005

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部